GBA Presents: RADIO SAVANT-!

[stonedinvestor]

Advent Technologies and DEPA Commercial, sign MoU for hydrogen projects 08/08 ADN Advent Technologies Holdings, Inc., an innovation-driven leader in the fuel cell and hydrogen technology space, announced the signing of a Memorandum of Understanding with DEPA Commercial , importer of pipeline gas and liquefied natural gas in Greece to enter into a strategic collaboration on hydrogen projects of common interest. The MoU sets out the framework for a forthcoming mutually binding agreement. The parties have preliminarily agreed to the following actions: Collaborate on the production of environmentally friendly hydrogen as a fuel with the participation of other major industrial partners. Co-develop a proprietary and highly differentiated CHP system ready for mass production with efficiency approaching 90% and with multi-fuel operating capabilities that can address the key current, future, and on-grid, off-grid operation modes and business cases. Create an innovation hub for the Greek hydrogen and fuel cell industry and develop synergies for promoting hydrogen and related technologies. DEPA's CEO, Dr. Konstantinos Xifaras, stated: "Our cooperation with Advent marks another important milestone in the advancement of hydrogen technologies in our country. DEPA has been closely following and actively pushed for the developments in the hydrogen sector, while Advent has extensive electrochemistry and engineering expertise and a global scale of operations and manufacturing footprint. We look forward to working with Advent's team of experts, contributing to the diversification of the national energy mix and the security of the energy supply while simultaneously strengthening the national economy."

Advent receives official ratification from EU for 'Green HiPo' IPCEI Project 07/18 ADN Advent Technologies Holding announces that its Green HiPo projec under the framework of the Important Projects of Common European Interest IPCEI Hydrogen - Technology, has now received official ratification from the European Commission of the European Union . The ratification of Green HiPo was amongst 41 projects under the umbrella "IPCEI Hy2Tech" jointly prepared and notified by fifteen Member States: Austria, Belgium, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Slovakia, and Spain. The Member States will provide up to EUR 5.4 billion in public funding, which is expected to unlock an additional EUR 8.8 billion in private investments. As part of this IPCEI, 35 companies with activities in one or more Member States, including small and medium-sized enterprises and start-ups, will participate in these 41 projects. Advent is one of only eight SMEs to have received ratification. The direct participants will closely cooperate with each other through numerous planned collaborations and also with more than 300 external partners, such as universities, research organizations, and SMEs across Europe.
$13 B opportunity <--------

 

[stonedinvestor]

GBA Initiates Coverage.>>>>>>>>Bridgeline Digital,

BLIN- With a four-week price change of 26.5%,

While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. BLIN meets this criterion too, as the stock gained 14.7% over the past 12 weeks.

Moreover, the momentum for BLIN is fast paced, as the stock currently has a beta of 2.48. This indicates that the stock moves 148% higher than the market in either direction.

Given this price performance, it is no surprise that BLIN has a Momentum Score of B, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.

Most importantly, despite possessing fast-paced momentum features, BLIN is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. BLIN is currently trading at 0.90 times its sales. In other words, investors need to pay only 90 cents for each dollar of sales.

So, BLIN appears to have plenty of room to run>>>>>>>>

Aug 11---

Bridgeline Digital, Inc. (BLIN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 166.67%. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced earnings of $0.03, delivering a surprise of 150%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Bridgeline Digital, Inc. (BLIN)
NasdaqCM - NasdaqCM Real Time Price.
1.3700-0.0300(-2.14%)
At close: September 6 04:02PM EDT
1.5200+0.1500(+10.9489%)<-------------------
Pre-Market:8:37AM EDT

KEEP BUYING-! @$1.66

• CEO of Bridgeline Digital (BLIN) Roger Kahn purchased 79,820 shares of company stock at $1.58 per share for a total transaction amount of $126,060

• 
  
  

 

[stonedinvestor]

IDEA- Wolfspeed price target raised to $125 from $100 at Wells Fargo 06:44 WOLF Wells Fargo analyst Gary Mobley raised the firm's price target on Wolfspeed to $125 from $100 and keeps an Overweight rating on the shares following much better-than-expected Q4 results and above-consensus Q1 guidance. The analyst believes the most important takeaways from results, guide and commentary are the company believing it is possible to deliver 30%-40% upside to the original $2.1B fiscal 2026 revenue forecast, seeing $2.6B of design-ins in Q4, Wolfspeed's opportunity pipeline now standing at over $35B, Mohawk Valley remaining on target to ramp in 2023, and Wolfspeed already considering expansion opportunities in both devices and materials.

This was our upteenth entry into this name. we had a fine $88 lot but flipped it for $4 then got back in @ $ 108 area after a spike not happy- played it porly but we currently are at $122!
and 2 of the Children still have it from $88 Congrats!

WOLF the Number 1 semi stk.

 

[stonedinvestor]

--Shoals Technologies, Nextracker unveil new North-South BLA trunk bus product

--

Roughly Dec 2021 we used INVZ as a gummy @ $7<----------------

stonedinvestor said:
Innoviz Technologies Ltd. (INVZ)- something still cooking here- gummy from 1-2 weeks ago. Over 4 mil shares today finished up.
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.18+0.15 (+2.13%)
At close: 04:00PM EST
7.20 +0.02 (+0.28%)


NOW)
Innoviz says forward-looking order book updated to $6.6B after CARIAD win 07:28 INVZ, VWAGY Innoviz Technologies (INVZ) announced that its recent design win is with CARIAD SE. CARIAD selected Innoviz to be its supplier and deliverer of advanced ADAS features for the segment of automated vehicles within the Volkswagen (VWAGY) brands. "We are thrilled to work with the CARIAD team and be a supplier of LiDAR sensors and perception software to support safe mobility for vehicles launching from the middle of the decade. CARIAD is a leading player in the transformation of the whole automotive space. We are proud to be part of their mission," said Innoviz CEO and Co-Founder, Omer Keilaf. "This is Innoviz's third design win with a major automaker and first deal as a Tier-1 supplier. With its third design win, Innoviz's forward-looking order book was updated to $6.6 billion," the company added.

INVZ is now $4.00

I have won big, lost big and won big again on this name but today is a special day.!!! Oneof our little under the radar plays has We got big boy coverage!!!! alert alert********

INVZ BGA $4--------$6 and buy more!

Innoviz Technologies Ltd. (INVZ)
NasdaqCM - NasdaqCM Real Time Price.
5.54+0.09(+1.65%)
At close: September 19 04:00PM EDT
6.00+0.46(+8.28%)<-------------------
Pre-Market:08:25AM EDT

 

[stonedinvestor]

I ask people all the time that I meet in bars what do you like best about GBA and the answers are varied there's a group that just like the morning notes and there is a group that just likes me and Vans bantering and Van's predicaments he gets himself into and the biggest group of readers by far seem to really like the under the covers stocks we find for you all. Names that others do not know....

Innoviz is one such name-!-- Innoviz Technologies up 8.5% in pre-market after JPMorgan Overweight initiation 08:05 INVZ

 

[stonedinvestor]

Good Morning Good Morning. I'm thinking about doing something naughty, my girl at the gym I can't take it anymore... I'm so nervous I'm going to corner her and whisper " Would you like to make a lot of money quickly " I think that's the least cringy of the opening salvos...

Bank of America CFO: Consumer still in 'great shape' » Ta da!!!!

Cognex raises Q3 revenue view to $195M-$205M from $160M-$180M 16:09 CGNX Consensus $170.4M. The company states: "This increase is primarily due to the company's ability to fulfill customer demand sooner than anticipated due to strong progress in replenishing component inventory destroyed in the previously disclosed fire at the company's primary contract manufacturer. Cognex will host its Analyst Day for institutional investors and sell-side analysts on Tuesday, September 20, 2022 at the company's headquarters in Natick, Massachusetts. At the meeting, Cognex will present an updated view of its estimated served market valued at $6.5B, up from $4.2B last estimated in 2019, including a long-term compound annual revenue growth target of 15% over the medium-to-long term. "

-> Cognex jumps 10% to $46.04 after raising Q3 revenue guidance

eBay Q3 appears to be tracking in line, says Baird 06:53 EBAY Baird analyst Colin Sebastian said he remains comfortable with his Q3 estimates for eBay based on quarter-to-date volumes from his eBay tracker, although admittedly, macro-disruptions internationally could be a bit of a blind spot for his tracker. He said looking further ahead, he views improving GMV trends as a potential catalyst for the shares into 2023. Sebastian maintains his Outperform rating and $60 price target on eBay shares.

Elastic price target raised to $90 from $80 at Jefferies 04:43 ESTC Jefferies analyst

Viper Energy initiated with an Overweight at KeyBanc 16:16 VNOM KeyBanc analyst Tim Rezvan initiated coverage of Viper Energy with an Overweight rating and $39 price target.

Fisker, Wallbox partner on home EV charging solutions 06:34 FSR, WBX Fisker (FSR) and Wallbox

Zedge announces pilot program with Saregama master recordings for ringtones 06:37 ZDGE Zedge announced a pilot program that avails Zedge users with access to 1,000 of Saregama's master recordings for ringtones. Saregama India owns the largest music archives in India and one of the biggest in the world.

 

[vanzandt]

Good Morning Good Morning. I'm thinking about doing something naughty, my girl at the gym I can't take it anymore... I'm so nervous I'm going to corner her and whisper " Would you like to make a lot of money quickly " I think that's the least cringy of the opening salvos...

.

lol. omg

Stoney!!!!
Quit suggesting these dog stocks.
Look at the Advent chart for (big) Pete's sake.

The savant will be shorting The Wolf today on your upgrade.
We make more money fading you.... even Cramer agrees.

 

[stonedinvestor]

Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing

Praxis Precision Medicines, Inc.

First use of Ciitizen platform as source of real-world data in regulatory filing

SAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) --Invitae(NYSE: NVTA) andPraxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy (DEE). Praxisannouncedearlier this month that the U.S. Food and Drug Administration (FDA) cleared the IND application for the initial dose cohort for the PRAX-222 EMBRAVE clinical study.

For many well-established diseases, natural history studies and other rich data sets are available to support regulatory interactions and IND applications. For many rare diseases, including certain severe genetic pediatric epilepsies such as SCN2A-DEE, natural history studies are not yet available to document the high disease burden and significant unmet medical need. In addition, the usual method of collecting these data by having patients seen at many geographically dispersed sites is cost intensive, time consuming and not well suited to rare diseases. Invitae’s Ciitizen platform enables the rapid and comprehensive collection and analysis of medical history data, which supports understanding of the patient population and disease severity, may be used as natural history data for regulatory submissions, and can inform protocol design and inclusion and exclusion criteria for clinical studies.

“The comprehensive real-world clinical evidence generated through Invitae’s Ciitizen platform was a critical component to the PRAX-222 IND application, integrating a significant amount of natural history data in a highly efficient manner to help bring PRAX-222 one step closer to SCN2A-DEE patients,” said Steven Petrou, Ph.D., co-founder and chief scientific officer of Praxis. “In order to make real progress and offer hope to patients living with SCN2A-DEE and their caregivers, it requires a committed ecosystem and a community willing to consider innovative approaches to drug development. We look forward to our continued partnership with Invitae for PRAX-222 and for other precision medicines targeting rare genetic epilepsies with high unmet need.”

The data, collected on behalf of SCN2A-DEE patients or their parents/guardians, is de-identified and shared with their consent, and represent the richest aggregation of real-world clinical evidence for SCN2A-DEE patients. The data generated by Invitae’s Ciitizen platform is comprehensive, leveraging the HIPAA right of access to gather full medical records, longitudinally, from all of the patients’ sites of care. This approach addresses many of the limitations of other data sources, such as de-identified provider electronic medical record and claims data, that were raised by the FDA in recent draft guidance documents on the use of real-world data in regulatory submissions. This novel data collection and extraction model also addresses many of the logistical, financial, and methodological limitations of the site-based natural history studies, by rapidly enrolling a diverse and representative sample of patients directly without the need to engage with sites for recruitment and data collection. Additionally, the real-world data set underlying this natural history study provides a unique data collection and sharing model wherein the patients, patient advocacy groups and other researchers all have access to the data collected. Patients have complete access to the records for their own use and are also able to remain involved and informed about the research throughout the study, highlighting the benefits of this unique patient-centered research model.

“This is, to my knowledge, the first instance of a patient-mediated medical records platform being utilized as the primary natural history data source for a successful IND filing with the FDA,” stated Alexandra Berk, medical affairs director at Invitae. “It’s an important development in terms of the FDA’s openness to include novel data sources as part of the regulatory process.”

“We are thrilled to partner with Praxis and see how our Ciitizen platform’s high quality data can move the needle forward for patients living with this rare, genetic epilepsy,” said Robert Nussbaum, M.D., chief medical officer of Invitae. “Our goal is to advance the understanding of SCN2A-DEE and other diseases and utilize these data to bring new therapies to market faster. Ciitizen is a compelling platform for rapidly gathering both genotypic and phenotypic data with patient consent and engagement for natural history studies for rare diseases, data that are essential to regulatory processes and for developing new therapies.”


Invitae Corporation (NVTA)- GBA UPGRADE AT LOW!
NYSE - NYSE Delayed Price.
3.1300-0.0500(-1.57%)
At close: September 19 04:00PM EDT
3.0300-0.10(-3.19%)<------------------- Buy me Target $5 +
Pre-Market:09:05AM EDT


3,000 employees!

Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

 

[vanzandt]

Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing

Praxis Precision Medicines, Inc.

First use of Ciitizen platform as source of real-world data in regulatory filing

SAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) --Invitae(NYSE: NVTA) andPraxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy (DEE). Praxisannouncedearlier this month that the U.S. Food and Drug Administration (FDA) cleared the IND application for the initial dose cohort for the PRAX-222 EMBRAVE clinical study.

For many well-established diseases, natural history studies and other rich data sets are available to support regulatory interactions and IND applications. For many rare diseases, including certain severe genetic pediatric epilepsies such as SCN2A-DEE, natural history studies are not yet available to document the high disease burden and significant unmet medical need. In addition, the usual method of collecting these data by having patients seen at many geographically dispersed sites is cost intensive, time consuming and not well suited to rare diseases. Invitae’s Ciitizen platform enables the rapid and comprehensive collection and analysis of medical history data, which supports understanding of the patient population and disease severity, may be used as natural history data for regulatory submissions, and can inform protocol design and inclusion and exclusion criteria for clinical studies.

“The comprehensive real-world clinical evidence generated through Invitae’s Ciitizen platform was a critical component to the PRAX-222 IND application, integrating a significant amount of natural history data in a highly efficient manner to help bring PRAX-222 one step closer to SCN2A-DEE patients,” said Steven Petrou, Ph.D., co-founder and chief scientific officer of Praxis. “In order to make real progress and offer hope to patients living with SCN2A-DEE and their caregivers, it requires a committed ecosystem and a community willing to consider innovative approaches to drug development. We look forward to our continued partnership with Invitae for PRAX-222 and for other precision medicines targeting rare genetic epilepsies with high unmet need.”

The data, collected on behalf of SCN2A-DEE patients or their parents/guardians, is de-identified and shared with their consent, and represent the richest aggregation of real-world clinical evidence for SCN2A-DEE patients. The data generated by Invitae’s Ciitizen platform is comprehensive, leveraging the HIPAA right of access to gather full medical records, longitudinally, from all of the patients’ sites of care. This approach addresses many of the limitations of other data sources, such as de-identified provider electronic medical record and claims data, that were raised by the FDA in recent draft guidance documents on the use of real-world data in regulatory submissions. This novel data collection and extraction model also addresses many of the logistical, financial, and methodological limitations of the site-based natural history studies, by rapidly enrolling a diverse and representative sample of patients directly without the need to engage with sites for recruitment and data collection. Additionally, the real-world data set underlying this natural history study provides a unique data collection and sharing model wherein the patients, patient advocacy groups and other researchers all have access to the data collected. Patients have complete access to the records for their own use and are also able to remain involved and informed about the research throughout the study, highlighting the benefits of this unique patient-centered research model.

“This is, to my knowledge, the first instance of a patient-mediated medical records platform being utilized as the primary natural history data source for a successful IND filing with the FDA,” stated Alexandra Berk, medical affairs director at Invitae. “It’s an important development in terms of the FDA’s openness to include novel data sources as part of the regulatory process.”

“We are thrilled to partner with Praxis and see how our Ciitizen platform’s high quality data can move the needle forward for patients living with this rare, genetic epilepsy,” said Robert Nussbaum, M.D., chief medical officer of Invitae. “Our goal is to advance the understanding of SCN2A-DEE and other diseases and utilize these data to bring new therapies to market faster. Ciitizen is a compelling platform for rapidly gathering both genotypic and phenotypic data with patient consent and engagement for natural history studies for rare diseases, data that are essential to regulatory processes and for developing new therapies.”


Invitae Corporation (NVTA)- GBA UPGRADE AT LOW!
NYSE - NYSE Delayed Price.
3.1300-0.0500(-1.57%)
At close: September 19 04:00PM EDT
3.0300-0.10(-3.19%)<------------------- Buy me Target $5 +
Pre-Market:09:05AM EDT


3,000 employees!

Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

They'll be buying 23andMe.

"“This is, to my knowledge, the first instance of a patient-mediated medical records platform being utilized as the primary natural history data source for a successful IND filing with the FDA,”

This is old school tech.
We map the genome now Stoney.
Get with the times.

 

[stonedinvestor]

Van RE WOLF-

We bought 8/22 after the large spike and slight retrace. Our upgrade would be from $107 shorting that at $122 is going to be difficult.

We did not upgrade today.